David Komander part of collaborative consortium in the field of deubiquitinating enzymes.

FORMA Therapeutics and Cancer Research Technology, Ltd (CRT) have announced the formation of two new virtual Asset Discovery and Development Companies (ADDCos) to represent the collective efforts of the consortium in the field of deubiquitinating enzymes (DUBs). ADDCos are virtual companies seeking to achieve rapid innovation in a compelling scientific area through the collaboration of academic thought leaders, FORMA drug discovery scientists and a world class development network. More…